Skip to main content
. 2026 Feb 28;27(5):2305. doi: 10.3390/ijms27052305
DC Dendritic cell
DEX Dendritic cell-derived exosome
PLPC Phospholipoproteic complex
TME Tumor microenvironment
MHC Major histocompatibility complex
MHC-I Major histocompatibility complex class I
MHC-II Major histocompatibility complex class II
CD Cluster of differentiation
CD80 Cluster of differentiation 80
CD86 Cluster of differentiation 86
HLA-DR Human leukocyte antigen DR
IFN-γ Interferon gamma
IL Interleukin
IL-10 Interleukin 10
IL-6 Interleukin 6
NAM New Approach Methodologies
Lo Liquid-ordered phase
Ld Liquid-disordered phase
STIP Structural Traceability Immunophenotyping Platform
PD-1 Programmed cell death protein 1
PD-L1 Programmed death-ligand 1
CCR7 C–C chemokine receptor type 7
ROS Reactive oxygen species
TCR T cell receptor
CAR-T Chimeric antigen receptor T cells
RECIST Response Evaluation Criteria in Solid Tumors
iRECIST Immune Response Evaluation Criteria in Solid Tumors
PK Pharmacokinetics
PD Pharmacodynamics